Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hematopoietic Stem Cell Transplantation | 22 | 2024 | 5672 | 0.920 |
Why?
|
Yttrium Radioisotopes | 5 | 2015 | 107 | 0.850 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 5 | 2023 | 1405 | 0.840 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 11 | 2015 | 694 | 0.780 |
Why?
|
Hodgkin Disease | 8 | 2022 | 1378 | 0.740 |
Why?
|
Lymphoma, B-Cell | 8 | 2021 | 940 | 0.570 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 20 | 2021 | 11742 | 0.510 |
Why?
|
Transplantation, Autologous | 14 | 2023 | 2115 | 0.460 |
Why?
|
Data Mining | 1 | 2019 | 551 | 0.460 |
Why?
|
Graft vs Host Disease | 8 | 2024 | 3029 | 0.440 |
Why?
|
Antibodies, Monoclonal | 11 | 2015 | 9177 | 0.440 |
Why?
|
Therapeutics | 1 | 2013 | 113 | 0.410 |
Why?
|
Guillain-Barre Syndrome | 1 | 2014 | 127 | 0.400 |
Why?
|
Remission Induction | 12 | 2016 | 2397 | 0.380 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2019 | 1640 | 0.350 |
Why?
|
Dendritic Cells | 9 | 2014 | 2747 | 0.330 |
Why?
|
Antineoplastic Agents | 13 | 2022 | 13642 | 0.330 |
Why?
|
Cancer Vaccines | 6 | 2016 | 1051 | 0.320 |
Why?
|
Lymphoma, Primary Effusion | 1 | 2008 | 17 | 0.320 |
Why?
|
Lymphoma, Non-Hodgkin | 5 | 2017 | 1374 | 0.310 |
Why?
|
Hematopoietic Stem Cell Mobilization | 4 | 2017 | 225 | 0.310 |
Why?
|
Multiple Myeloma | 8 | 2013 | 5146 | 0.310 |
Why?
|
Radioimmunotherapy | 4 | 2015 | 91 | 0.290 |
Why?
|
Information Storage and Retrieval | 1 | 2013 | 819 | 0.290 |
Why?
|
Granulocyte Colony-Stimulating Factor | 4 | 2012 | 629 | 0.280 |
Why?
|
Mucin-1 | 4 | 2017 | 540 | 0.280 |
Why?
|
Antigens, CD34 | 3 | 2024 | 658 | 0.260 |
Why?
|
Extravasation of Diagnostic and Therapeutic Materials | 1 | 2006 | 101 | 0.250 |
Why?
|
Lymphoma, Mantle-Cell | 2 | 2020 | 237 | 0.250 |
Why?
|
Anilides | 2 | 2017 | 411 | 0.240 |
Why?
|
Leukemia, Myeloid, Acute | 6 | 2017 | 3615 | 0.230 |
Why?
|
Electronic Health Records | 2 | 2019 | 4811 | 0.230 |
Why?
|
Salvage Therapy | 3 | 2021 | 1263 | 0.220 |
Why?
|
Doxorubicin | 6 | 2021 | 2224 | 0.200 |
Why?
|
Nitrogen Mustard Compounds | 2 | 2014 | 44 | 0.200 |
Why?
|
Stem Cell Transplantation | 5 | 2023 | 1600 | 0.190 |
Why?
|
Lymphoma, Follicular | 3 | 2022 | 457 | 0.170 |
Why?
|
Antibodies, Bispecific | 1 | 2022 | 196 | 0.170 |
Why?
|
Hematologic Neoplasms | 3 | 2024 | 1896 | 0.160 |
Why?
|
Etoposide | 4 | 2021 | 634 | 0.160 |
Why?
|
Disease-Free Survival | 10 | 2019 | 6815 | 0.160 |
Why?
|
Radiation Injuries | 1 | 2006 | 1189 | 0.160 |
Why?
|
Health Records, Personal | 1 | 2019 | 127 | 0.150 |
Why?
|
Vinblastine | 1 | 2019 | 488 | 0.150 |
Why?
|
Leukocytes, Mononuclear | 4 | 2023 | 1844 | 0.140 |
Why?
|
Databases, Factual | 1 | 2013 | 7968 | 0.140 |
Why?
|
Quinazolinones | 1 | 2019 | 221 | 0.140 |
Why?
|
Antigens, CD | 3 | 2014 | 4001 | 0.140 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 2 | 2012 | 263 | 0.140 |
Why?
|
T-Lymphocytes | 5 | 2018 | 10194 | 0.130 |
Why?
|
Dacarbazine | 1 | 2019 | 559 | 0.130 |
Why?
|
Skin Diseases, Parasitic | 1 | 2016 | 13 | 0.130 |
Why?
|
Amebiasis | 1 | 2016 | 33 | 0.130 |
Why?
|
Aged | 33 | 2024 | 169310 | 0.130 |
Why?
|
Boronic Acids | 3 | 2010 | 915 | 0.130 |
Why?
|
Purines | 1 | 2019 | 607 | 0.130 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2023 | 9280 | 0.120 |
Why?
|
Ifosfamide | 3 | 2013 | 232 | 0.120 |
Why?
|
Phenotype | 1 | 2013 | 16592 | 0.120 |
Why?
|
Humans | 70 | 2024 | 761596 | 0.120 |
Why?
|
Survival Rate | 9 | 2021 | 12723 | 0.120 |
Why?
|
Rifamycins | 1 | 2014 | 26 | 0.120 |
Why?
|
Cell Proliferation | 6 | 2017 | 10451 | 0.120 |
Why?
|
Graft vs Leukemia Effect | 1 | 2014 | 121 | 0.110 |
Why?
|
Miller Fisher Syndrome | 1 | 2014 | 7 | 0.110 |
Why?
|
Middle Aged | 40 | 2024 | 220921 | 0.110 |
Why?
|
Transplantation, Homologous | 5 | 2024 | 4807 | 0.110 |
Why?
|
Pyrazines | 3 | 2010 | 1202 | 0.110 |
Why?
|
fms-Like Tyrosine Kinase 3 | 1 | 2017 | 495 | 0.110 |
Why?
|
Cyclophosphamide | 3 | 2021 | 2220 | 0.110 |
Why?
|
Lymphocyte Transfusion | 1 | 2014 | 232 | 0.110 |
Why?
|
Stiff-Person Syndrome | 1 | 2013 | 31 | 0.110 |
Why?
|
Gangliosides | 1 | 2014 | 132 | 0.110 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2017 | 617 | 0.110 |
Why?
|
Plasmapheresis | 1 | 2014 | 206 | 0.110 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 1 | 2015 | 212 | 0.110 |
Why?
|
Opportunistic Infections | 1 | 2016 | 376 | 0.100 |
Why?
|
Herpesvirus 3, Human | 1 | 2014 | 159 | 0.100 |
Why?
|
Documentation | 1 | 2019 | 897 | 0.100 |
Why?
|
Antigens, CD1 | 2 | 2008 | 439 | 0.100 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2014 | 2009 | 0.100 |
Why?
|
Immunologic Factors | 2 | 2013 | 1590 | 0.100 |
Why?
|
Methylprednisolone | 1 | 2014 | 385 | 0.100 |
Why?
|
Peptides | 2 | 2015 | 4358 | 0.100 |
Why?
|
Cluster Analysis | 1 | 2019 | 2707 | 0.100 |
Why?
|
Mitoxantrone | 2 | 2003 | 148 | 0.100 |
Why?
|
Neoplasm, Residual | 3 | 2023 | 1008 | 0.100 |
Why?
|
Virus Activation | 1 | 2014 | 322 | 0.100 |
Why?
|
Sulfonamides | 1 | 2021 | 1979 | 0.100 |
Why?
|
Transplantation Conditioning | 1 | 2018 | 1590 | 0.100 |
Why?
|
Heterocyclic Compounds | 1 | 2012 | 246 | 0.100 |
Why?
|
Positron-Emission Tomography | 4 | 2015 | 6484 | 0.090 |
Why?
|
Drug Resistance, Neoplasm | 4 | 2021 | 5305 | 0.090 |
Why?
|
Herpes Zoster | 1 | 2014 | 253 | 0.090 |
Why?
|
Male | 37 | 2024 | 360846 | 0.090 |
Why?
|
Continuous Positive Airway Pressure | 1 | 2016 | 575 | 0.090 |
Why?
|
Cytarabine | 3 | 2020 | 698 | 0.090 |
Why?
|
Leukapheresis | 3 | 2014 | 134 | 0.090 |
Why?
|
Apoptosis Regulatory Proteins | 2 | 2015 | 1136 | 0.090 |
Why?
|
Adult | 34 | 2024 | 221210 | 0.090 |
Why?
|
Immunity, Cellular | 2 | 2013 | 1560 | 0.080 |
Why?
|
Thalidomide | 2 | 2012 | 885 | 0.080 |
Why?
|
Antigens, Neoplasm | 2 | 2016 | 1993 | 0.080 |
Why?
|
Autoantigens | 1 | 2014 | 891 | 0.080 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2014 | 664 | 0.080 |
Why?
|
Consciousness Disorders | 1 | 2014 | 441 | 0.080 |
Why?
|
Androgen Antagonists | 1 | 1998 | 1410 | 0.080 |
Why?
|
Granzymes | 1 | 2010 | 277 | 0.080 |
Why?
|
Hematopoietic Stem Cells | 2 | 2012 | 3397 | 0.070 |
Why?
|
Female | 40 | 2024 | 392705 | 0.070 |
Why?
|
Vidarabine | 1 | 2009 | 336 | 0.070 |
Why?
|
Skin Neoplasms | 2 | 2018 | 5821 | 0.070 |
Why?
|
International Classification of Diseases | 1 | 2013 | 910 | 0.070 |
Why?
|
Immunophenotyping | 6 | 2013 | 1869 | 0.070 |
Why?
|
Maximum Tolerated Dose | 2 | 2021 | 883 | 0.070 |
Why?
|
Pancreas | 1 | 2014 | 1691 | 0.070 |
Why?
|
Herpesviridae Infections | 1 | 2008 | 270 | 0.070 |
Why?
|
Venous Thromboembolism | 1 | 2020 | 1866 | 0.070 |
Why?
|
Vaccination | 2 | 2016 | 3384 | 0.070 |
Why?
|
Antigens, Differentiation | 1 | 2010 | 909 | 0.070 |
Why?
|
Thrombocytopenia | 1 | 2015 | 1182 | 0.070 |
Why?
|
Combined Modality Therapy | 4 | 2014 | 8527 | 0.070 |
Why?
|
Radiopharmaceuticals | 2 | 2014 | 2650 | 0.070 |
Why?
|
Herpesvirus 8, Human | 1 | 2008 | 255 | 0.070 |
Why?
|
Follow-Up Studies | 9 | 2021 | 39106 | 0.070 |
Why?
|
Dyspnea | 1 | 2014 | 1347 | 0.070 |
Why?
|
Glycoproteins | 1 | 2014 | 2203 | 0.070 |
Why?
|
Cerebellum | 1 | 2013 | 1501 | 0.060 |
Why?
|
Cell Fusion | 3 | 2011 | 294 | 0.060 |
Why?
|
Chronic Disease | 5 | 2023 | 9319 | 0.060 |
Why?
|
Pyridines | 1 | 2017 | 2875 | 0.060 |
Why?
|
Intestines | 1 | 2014 | 1910 | 0.060 |
Why?
|
Neoplastic Stem Cells | 1 | 2013 | 1351 | 0.060 |
Why?
|
Prednisone | 2 | 2021 | 1563 | 0.060 |
Why?
|
Software | 1 | 2019 | 4434 | 0.060 |
Why?
|
Immunosuppressive Agents | 1 | 2018 | 4176 | 0.060 |
Why?
|
Autoantibodies | 1 | 2014 | 2118 | 0.060 |
Why?
|
Aged, 80 and over | 9 | 2019 | 58984 | 0.060 |
Why?
|
Treatment Outcome | 16 | 2021 | 64685 | 0.060 |
Why?
|
Interleukin-2 | 1 | 2011 | 1889 | 0.060 |
Why?
|
T-Lymphocytes, Regulatory | 3 | 2016 | 3080 | 0.060 |
Why?
|
Liposomes | 1 | 2008 | 783 | 0.060 |
Why?
|
Survival Analysis | 5 | 2019 | 10090 | 0.060 |
Why?
|
Lung Diseases | 1 | 2014 | 1909 | 0.060 |
Why?
|
Pilot Projects | 2 | 2013 | 8633 | 0.060 |
Why?
|
Intestinal Mucosa | 1 | 2014 | 3032 | 0.050 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2018 | 4024 | 0.050 |
Why?
|
Th1 Cells | 1 | 2008 | 1036 | 0.050 |
Why?
|
Killer Cells, Natural | 3 | 2008 | 2201 | 0.050 |
Why?
|
Antigens, CD19 | 2 | 2022 | 424 | 0.050 |
Why?
|
Acute Kidney Injury | 1 | 2014 | 1924 | 0.050 |
Why?
|
Apoptosis | 2 | 2015 | 9490 | 0.050 |
Why?
|
Immunotherapy | 3 | 2013 | 4652 | 0.050 |
Why?
|
Filgrastim | 1 | 2001 | 132 | 0.050 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 2 | 2016 | 178 | 0.050 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2008 | 891 | 0.050 |
Why?
|
HIV | 1 | 2008 | 1582 | 0.050 |
Why?
|
Immunoenzyme Techniques | 2 | 2015 | 1704 | 0.050 |
Why?
|
Viral Vaccines | 1 | 2006 | 596 | 0.050 |
Why?
|
Pneumococcal Vaccines | 1 | 2005 | 397 | 0.050 |
Why?
|
Protein Kinase Inhibitors | 1 | 2017 | 5672 | 0.050 |
Why?
|
Internet | 1 | 2013 | 3093 | 0.040 |
Why?
|
Bone Marrow Transplantation | 2 | 1998 | 2693 | 0.040 |
Why?
|
Antibody Formation | 1 | 2005 | 1395 | 0.040 |
Why?
|
Breast Neoplasms | 7 | 2002 | 21019 | 0.040 |
Why?
|
Neoplasm Staging | 1 | 2015 | 11120 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 3 | 2015 | 20568 | 0.040 |
Why?
|
Mice, Inbred NOD | 2 | 2015 | 1827 | 0.040 |
Why?
|
Lymphoma | 1 | 2009 | 1901 | 0.040 |
Why?
|
Safety-Based Drug Withdrawals | 1 | 2019 | 36 | 0.040 |
Why?
|
Mice, SCID | 2 | 2015 | 2626 | 0.040 |
Why?
|
Vincristine | 1 | 2021 | 1036 | 0.040 |
Why?
|
Flow Cytometry | 3 | 2015 | 5870 | 0.040 |
Why?
|
Algorithms | 1 | 2019 | 14033 | 0.040 |
Why?
|
Lectins, C-Type | 1 | 2001 | 585 | 0.040 |
Why?
|
Clinical Trials as Topic | 4 | 2017 | 8002 | 0.040 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2020 | 344 | 0.040 |
Why?
|
Lymphocyte Activation | 4 | 2012 | 5485 | 0.040 |
Why?
|
Transplantation Immunology | 1 | 2000 | 532 | 0.040 |
Why?
|
Steroids | 1 | 2023 | 929 | 0.040 |
Why?
|
Ondansetron | 1 | 1998 | 95 | 0.040 |
Why?
|
Waldenstrom Macroglobulinemia | 1 | 2007 | 1073 | 0.040 |
Why?
|
Recurrence | 5 | 2014 | 8466 | 0.040 |
Why?
|
Enoxaparin | 1 | 2020 | 391 | 0.040 |
Why?
|
Tosyl Compounds | 1 | 1998 | 115 | 0.040 |
Why?
|
Flutamide | 1 | 1998 | 95 | 0.040 |
Why?
|
Young Adult | 6 | 2024 | 59260 | 0.040 |
Why?
|
Plasminogen Activator Inhibitor 1 | 1 | 1998 | 277 | 0.040 |
Why?
|
Confidence Intervals | 1 | 2003 | 2927 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 4576 | 0.030 |
Why?
|
Antiemetics | 1 | 1998 | 186 | 0.030 |
Why?
|
Purpura, Thrombotic Thrombocytopenic | 1 | 1998 | 131 | 0.030 |
Why?
|
Cytotoxicity, Immunologic | 2 | 2011 | 1351 | 0.030 |
Why?
|
Blotting, Western | 2 | 2015 | 5035 | 0.030 |
Why?
|
Anti-HIV Agents | 1 | 2012 | 4527 | 0.030 |
Why?
|
Drug Administration Schedule | 4 | 2012 | 4853 | 0.030 |
Why?
|
Lymph Nodes | 2 | 2006 | 3465 | 0.030 |
Why?
|
Acanthamoeba castellanii | 1 | 2016 | 9 | 0.030 |
Why?
|
Th2 Cells | 1 | 2001 | 1060 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2018 | 15633 | 0.030 |
Why?
|
Vitamin D | 1 | 2010 | 3303 | 0.030 |
Why?
|
Anti-Bacterial Agents | 1 | 2014 | 7406 | 0.030 |
Why?
|
Melphalan | 3 | 2002 | 420 | 0.030 |
Why?
|
Glucocorticoids | 2 | 2018 | 2161 | 0.030 |
Why?
|
Carboplatin | 2 | 2013 | 794 | 0.030 |
Why?
|
Vomiting | 1 | 1998 | 651 | 0.030 |
Why?
|
Prostatic Neoplasms | 1 | 1998 | 11122 | 0.030 |
Why?
|
Interleukin-4 | 2 | 2014 | 1149 | 0.030 |
Why?
|
Immunohistochemistry | 1 | 2008 | 11076 | 0.030 |
Why?
|
Retrospective Studies | 5 | 2024 | 80647 | 0.030 |
Why?
|
Antigens, CD1d | 2 | 2008 | 228 | 0.030 |
Why?
|
NADP | 1 | 2015 | 227 | 0.030 |
Why?
|
Dexamethasone | 2 | 2013 | 1948 | 0.030 |
Why?
|
Fatigue | 2 | 2012 | 1552 | 0.030 |
Why?
|
Bone Marrow Cells | 1 | 2001 | 2417 | 0.030 |
Why?
|
Cecum | 1 | 2014 | 233 | 0.030 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2021 | 4580 | 0.030 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 2015 | 412 | 0.030 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2022 | 2547 | 0.030 |
Why?
|
Prognosis | 4 | 2022 | 29629 | 0.030 |
Why?
|
Coculture Techniques | 1 | 2017 | 1341 | 0.030 |
Why?
|
Mutation | 1 | 2017 | 30053 | 0.030 |
Why?
|
Histocompatibility Testing | 1 | 2014 | 712 | 0.030 |
Why?
|
Glutathione | 1 | 2015 | 583 | 0.030 |
Why?
|
Nitriles | 1 | 1998 | 971 | 0.030 |
Why?
|
Immunotherapy, Adoptive | 1 | 2022 | 1469 | 0.030 |
Why?
|
Treatment Failure | 2 | 2013 | 2643 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2017 | 1702 | 0.020 |
Why?
|
Metalloendopeptidases | 1 | 1993 | 393 | 0.020 |
Why?
|
Blood Component Removal | 1 | 2012 | 132 | 0.020 |
Why?
|
Benzylamines | 1 | 2012 | 247 | 0.020 |
Why?
|
Th1-Th2 Balance | 1 | 2011 | 38 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2001 | 6534 | 0.020 |
Why?
|
Immunization | 2 | 2006 | 1227 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2017 | 988 | 0.020 |
Why?
|
Immune System | 1 | 2016 | 796 | 0.020 |
Why?
|
Time Factors | 5 | 2017 | 39969 | 0.020 |
Why?
|
Neoplasms | 1 | 2020 | 22173 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2016 | 1835 | 0.020 |
Why?
|
Thorax | 1 | 2014 | 555 | 0.020 |
Why?
|
Necrosis | 1 | 2015 | 1611 | 0.020 |
Why?
|
RNA, Messenger | 3 | 2015 | 12794 | 0.020 |
Why?
|
Lymphocyte Culture Test, Mixed | 2 | 2001 | 509 | 0.020 |
Why?
|
Cells, Cultured | 4 | 2014 | 18966 | 0.020 |
Why?
|
Immunocompromised Host | 1 | 2016 | 858 | 0.020 |
Why?
|
Carcinoma | 1 | 2002 | 2330 | 0.020 |
Why?
|
Genes, T-Cell Receptor beta | 1 | 2010 | 71 | 0.020 |
Why?
|
Observation | 1 | 2011 | 310 | 0.020 |
Why?
|
Drug Interactions | 1 | 2014 | 1416 | 0.020 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 2011 | 357 | 0.020 |
Why?
|
T-Lymphocyte Subsets | 2 | 2012 | 1802 | 0.020 |
Why?
|
Mitogens | 1 | 2010 | 230 | 0.020 |
Why?
|
Paclitaxel | 3 | 2002 | 1732 | 0.020 |
Why?
|
Adolescent | 4 | 2024 | 88326 | 0.020 |
Why?
|
Cohort Studies | 4 | 2018 | 41495 | 0.020 |
Why?
|
Cell Communication | 1 | 2017 | 1657 | 0.020 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 1998 | 1520 | 0.020 |
Why?
|
Antibodies, Protozoan | 1 | 2010 | 252 | 0.020 |
Why?
|
Sensation Disorders | 1 | 2010 | 160 | 0.020 |
Why?
|
Neoplasms, Second Primary | 1 | 2017 | 1052 | 0.020 |
Why?
|
Immunoblotting | 1 | 2012 | 1646 | 0.020 |
Why?
|
Atrophy | 1 | 2014 | 1633 | 0.020 |
Why?
|
Axilla | 2 | 2006 | 624 | 0.020 |
Why?
|
Antigens, Protozoan | 1 | 2010 | 316 | 0.020 |
Why?
|
Retreatment | 1 | 2010 | 598 | 0.020 |
Why?
|
Prostate-Specific Antigen | 1 | 1998 | 2469 | 0.020 |
Why?
|
Acute Disease | 1 | 2018 | 7237 | 0.020 |
Why?
|
Leukocyte Count | 1 | 2011 | 1596 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2015 | 6131 | 0.020 |
Why?
|
Radiography, Thoracic | 1 | 2014 | 1302 | 0.020 |
Why?
|
Neutropenia | 1 | 2012 | 885 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2013 | 2510 | 0.020 |
Why?
|
Reactive Oxygen Species | 1 | 2015 | 2139 | 0.020 |
Why?
|
Cisplatin | 1 | 2013 | 1652 | 0.020 |
Why?
|
Myelodysplastic Syndromes | 1 | 2017 | 1394 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2015 | 3605 | 0.020 |
Why?
|
Cell Polarity | 1 | 2010 | 636 | 0.020 |
Why?
|
Lymphocytes | 1 | 2014 | 2612 | 0.020 |
Why?
|
Colon | 1 | 2014 | 1792 | 0.020 |
Why?
|
Clone Cells | 1 | 2010 | 1659 | 0.020 |
Why?
|
Hematologic Diseases | 1 | 2010 | 496 | 0.020 |
Why?
|
Diagnosis, Differential | 2 | 2014 | 12973 | 0.020 |
Why?
|
Drug Resistance | 1 | 2011 | 1596 | 0.020 |
Why?
|
Disease Progression | 3 | 2011 | 13510 | 0.020 |
Why?
|
Sirolimus | 1 | 2012 | 1533 | 0.020 |
Why?
|
Lymphoproliferative Disorders | 1 | 2009 | 531 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2011 | 10766 | 0.020 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2015 | 2872 | 0.020 |
Why?
|
Animals | 4 | 2017 | 168475 | 0.020 |
Why?
|
Renal Dialysis | 1 | 2014 | 1796 | 0.010 |
Why?
|
Tissue Donors | 1 | 2014 | 2332 | 0.010 |
Why?
|
Administration, Oral | 1 | 2012 | 4021 | 0.010 |
Why?
|
Anticoagulants | 1 | 2020 | 4812 | 0.010 |
Why?
|
Forkhead Transcription Factors | 1 | 2011 | 1616 | 0.010 |
Why?
|
Antigen Presentation | 1 | 2010 | 1251 | 0.010 |
Why?
|
False Positive Reactions | 1 | 2006 | 957 | 0.010 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2011 | 1784 | 0.010 |
Why?
|
Oxidative Stress | 1 | 2015 | 3113 | 0.010 |
Why?
|
Mice | 3 | 2017 | 81539 | 0.010 |
Why?
|
Antigens, CD20 | 1 | 2004 | 200 | 0.010 |
Why?
|
Subtraction Technique | 1 | 2006 | 512 | 0.010 |
Why?
|
Lymphatic Metastasis | 2 | 2006 | 2915 | 0.010 |
Why?
|
Vaccines, Conjugate | 1 | 2005 | 328 | 0.010 |
Why?
|
Cell Line, Transformed | 1 | 2004 | 866 | 0.010 |
Why?
|
Anemia | 1 | 2012 | 1509 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2014 | 4352 | 0.010 |
Why?
|
Neoplasm Metastasis | 3 | 2002 | 4915 | 0.010 |
Why?
|
Pain | 2 | 2010 | 5073 | 0.010 |
Why?
|
Thiotepa | 1 | 2002 | 66 | 0.010 |
Why?
|
Immunoglobulin M | 1 | 2007 | 1526 | 0.010 |
Why?
|
Cell Separation | 1 | 2008 | 1720 | 0.010 |
Why?
|
Biopsy | 1 | 2014 | 6766 | 0.010 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily B | 1 | 2001 | 84 | 0.010 |
Why?
|
Life Tables | 1 | 2002 | 364 | 0.010 |
Why?
|
Age Factors | 1 | 2018 | 18399 | 0.010 |
Why?
|
Interferon-gamma | 1 | 2010 | 3162 | 0.010 |
Why?
|
Gene Expression | 1 | 1993 | 7581 | 0.010 |
Why?
|
MicroRNAs | 1 | 2017 | 3816 | 0.010 |
Why?
|
Phytohemagglutinins | 1 | 2000 | 167 | 0.010 |
Why?
|
CD4-CD8 Ratio | 1 | 2000 | 114 | 0.010 |
Why?
|
Pneumococcal Infections | 1 | 2005 | 501 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2017 | 16990 | 0.010 |
Why?
|
Prospective Studies | 3 | 2014 | 54423 | 0.010 |
Why?
|
Signal Transduction | 2 | 2015 | 23447 | 0.010 |
Why?
|
Diagnostic Errors | 1 | 2006 | 1265 | 0.010 |
Why?
|
Hypersensitivity, Delayed | 1 | 2000 | 490 | 0.010 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2002 | 410 | 0.010 |
Why?
|
Antibodies, Bacterial | 1 | 2005 | 1469 | 0.010 |
Why?
|
Skin Tests | 1 | 2000 | 637 | 0.010 |
Why?
|
Radionuclide Imaging | 1 | 2002 | 1972 | 0.010 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2010 | 4369 | 0.010 |
Why?
|
United States | 2 | 2018 | 72340 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2014 | 9001 | 0.010 |
Why?
|
Progesterone | 1 | 2002 | 742 | 0.010 |
Why?
|
Antigens, Surface | 1 | 2001 | 1606 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2015 | 22176 | 0.010 |
Why?
|
Immunoglobulins | 1 | 2000 | 852 | 0.010 |
Why?
|
Bone Marrow | 1 | 2007 | 2911 | 0.010 |
Why?
|
Fluorouracil | 1 | 2002 | 1642 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2013 | 11530 | 0.010 |
Why?
|
HeLa Cells | 1 | 2001 | 3094 | 0.010 |
Why?
|
Methotrexate | 1 | 2002 | 1719 | 0.010 |
Why?
|
Estrogens | 1 | 2002 | 1522 | 0.010 |
Why?
|
Matrix Metalloproteinase 11 | 1 | 1993 | 15 | 0.010 |
Why?
|
Immunity | 1 | 2000 | 996 | 0.010 |
Why?
|
Cathepsin D | 1 | 1993 | 59 | 0.010 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2002 | 2827 | 0.010 |
Why?
|
Blotting, Northern | 1 | 1993 | 1545 | 0.010 |
Why?
|
Risk Factors | 1 | 2018 | 74213 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2002 | 12059 | 0.000 |
Why?
|
Carcinoma in Situ | 1 | 1993 | 791 | 0.000 |
Why?
|
Cell Line | 1 | 2001 | 15601 | 0.000 |
Why?
|
Proportional Hazards Models | 1 | 2002 | 12463 | 0.000 |
Why?
|
Cytokines | 1 | 2001 | 7396 | 0.000 |
Why?
|
Liver | 1 | 2002 | 7528 | 0.000 |
Why?
|
Melanoma | 1 | 1985 | 5709 | 0.000 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 1993 | 1085 | 0.000 |
Why?
|
Receptors, Estrogen | 1 | 1993 | 2209 | 0.000 |
Why?
|
Culture Techniques | 1 | 1985 | 531 | 0.000 |
Why?
|
Child, Preschool | 1 | 2005 | 42232 | 0.000 |
Why?
|
Mitosis | 1 | 1985 | 1188 | 0.000 |
Why?
|
Cell Division | 1 | 1985 | 4465 | 0.000 |
Why?
|
Child | 1 | 2005 | 80158 | 0.000 |
Why?
|